Last $8.20 USD
Change Today +0.29 / 3.67%
Volume 2.7M
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (XNPT) Snapshot

Open
$7.89
Previous Close
$7.91
Day High
$8.37
Day Low
$7.87
52 Week High
11/28/14 - $9.24
52 Week Low
05/9/14 - $3.15
Market Cap
510.4M
Average Volume 10 Days
953.0K
EPS TTM
$-0.94
Shares Outstanding
62.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XENOPORT INC (XNPT)

xenoport inc (XNPT) Related Businessweek News

No Related Businessweek News Found

xenoport inc (XNPT) Details

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders. It markets HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome, as well as for the management of postherpetic neuralgia in adults in the United States. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is being studied in a Phase I clinical trial for the treatment of psoriasis and/or relapsing forms of multiple sclerosis. In addition, it is developing product candidates that have completed Phase II clinical trial, including arbaclofen placarbil, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease. The company has strategic alliance with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

92 Employees
Last Reported Date: 02/28/14
Founded in 1999

xenoport inc (XNPT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $500.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $369.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $426.4K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $353.9K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $336.0K
Compensation as of Fiscal Year 2013.

xenoport inc (XNPT) Key Developments

Xenoport, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Xenoport, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, total revenues were $31.068 million against $2.527 million a year ago. Income from operations was $8.312 million loss from operation of against $18.753 million a year ago. Net income was $8.259 million or $0.13 per basic and diluted share against net loss of $18.816 million or $0.39 per basic and diluted share a year ago. For the nine months, total revenues were $39.777 million against $5.072 million a year ago. Loss from operations was $31.504 million $66.569 million a year ago. Net loss was $31.676 million or $0.52 per basic and diluted share against $6.745 million or $1.41 per basic and diluted share a year ago. The increases in Revenues were also due to increased HORIZANT net product sales.

Xenoport, Inc. to Report Q3, 2014 Results on Nov 04, 2014

Xenoport, Inc. announced that they will report Q3, 2014 results at 5:00 PM, US Eastern Standard Time on Nov 04, 2014

Xenoport, Inc., Q3 2014 Earnings Call, Nov 04, 2014

Xenoport, Inc., Q3 2014 Earnings Call, Nov 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNPT:US $8.20 USD +0.29

XNPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocon Ltd 435.00 INR -0.05
BioDelivery Sciences International Inc $13.82 USD +0.76
Depomed Inc $16.24 USD +0.52
Flamel Technologies SA $18.89 USD +2.44
PlasmaTech Biopharmaceuticals Inc $5.83 USD 0.00
View Industry Companies
 

Industry Analysis

XNPT

Industry Average

Valuation XNPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.0x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit www.xenoport.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.